James Dempsey - ViewRay Chief Scientific Officer, Director
| VRAYDelisted Stock | USD 0.04 0 5.67% |
Director
Dr. James F. Dempsey Ph.D. serves as Chief Scientific Officer and Director of the Company. He has served as our Chief Scientific Officer since founding ViewRay in March 2004. Dr. Dempsey was a member of the board of directors since January 2008. Dr. Dempsey brings more than 17 years of experience in the field of radiotherapy medical physics to ViewRay. He previously served as a faculty member in the University of Florida Department of Radiation Oncology as Assistant Professor from July 2001 to July 2007 and Associate Professor from July 2007 to January 2008 since 2008.
| Age | 52 |
| Tenure | 16 years |
| Professional Marks | Ph.D |
| Phone | 440 703 3210 |
| Web | https://www.viewray.com |
James Dempsey Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Dempsey against ViewRay stock is an integral part of due diligence when investing in ViewRay. James Dempsey insider activity provides valuable insight into whether ViewRay is net buyers or sellers over its current business cycle. Note, ViewRay insiders must abide by specific rules, including filing SEC forms every time they buy or sell ViewRay'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Dempsey over three months ago Disposition of 1512 shares by James Dempsey of Frontier Group at 6.89 subject to Rule 16b-3 |
ViewRay Management Efficiency
The company has return on total asset (ROA) of (0.2529) % which means that it has lost $0.2529 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0891) %, meaning that it created substantial loss on money invested by shareholders. ViewRay's management efficiency ratios could be used to measure how well ViewRay manages its routine affairs as well as how well it operates its assets and liabilities.ViewRay currently holds 86.4 M in liabilities with Debt to Equity (D/E) ratio of 0.54, which is about average as compared to similar companies. ViewRay has a current ratio of 2.98, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about ViewRay's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 8 records | DIRECTOR Age | ||
| Jeffrey Burbank | Artivion | 58 | |
| Cheryl Blanchard | Anika Therapeutics | 60 | |
| William Hawkins | Avanos Medical | 65 | |
| Heidi Kunz | Avanos Medical | 66 | |
| Maria Sainz | Avanos Medical | 55 | |
| Patrick OLeary | Avanos Medical | 63 | |
| Julie Shimer | Avanos Medical | 68 | |
| John Byrnes | Avanos Medical | 62 | |
Management Performance
| Return On Equity | -1.09 | |||
| Return On Asset | -0.25 |
ViewRay Leadership Team
Elected by the shareholders, the ViewRay's board of directors comprises two types of representatives: ViewRay inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ViewRay. The board's role is to monitor ViewRay's management team and ensure that shareholders' interests are well served. ViewRay's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ViewRay's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Robert McCormack, Chief Officer | ||
| Robert Fuchs, Chief Officer | ||
| Zachary Stassen, Chief Officer | ||
| James Dempsey, Chief Scientific Officer, Director | ||
| Martin MD, Chief Officer | ||
| JD Ziegler, Chief Officer | ||
| Karen Hackstaff, VP Marketing | ||
| Scott Drake, CEO Pres | ||
| Matt Harrison, Director Relations | ||
| Drew Hill, VP Devel |
ViewRay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ViewRay a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.09 | |||
| Return On Asset | -0.25 | |||
| Profit Margin | (1.04) % | |||
| Operating Margin | (1.02) % | |||
| Current Valuation | 11.47 M | |||
| Shares Outstanding | 183.4 M | |||
| Shares Owned By Insiders | 17.36 % | |||
| Shares Owned By Institutions | 74.60 % | |||
| Number Of Shares Shorted | 5.47 M | |||
| Price To Earning | (5.47) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in ViewRay Stock
If you are still planning to invest in ViewRay check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ViewRay's history and understand the potential risks before investing.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity |